Plasma p‐tau231 in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross‐sectional and longitudinal cohort study
INTRODUCTION Plasma phosphorylated tau (p‐tau)‐231 is a promising biomarker for Alzheimer's disease (AD), particularly in preclinical stages. We evaluated its diagnostic value in presenilin 1 (PSEN1) E280A mutation carriers versus non‐carriers and compared it to p‐tau217 and neurofilament light...
Saved in:
| Published in | Alzheimer's & dementia Vol. 21; no. 7; pp. e70421 - n/a |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
John Wiley and Sons Inc
01.07.2025
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1552-5260 1552-5279 1552-5279 |
| DOI | 10.1002/alz.70421 |
Cover
| Abstract | INTRODUCTION
Plasma phosphorylated tau (p‐tau)‐231 is a promising biomarker for Alzheimer's disease (AD), particularly in preclinical stages. We evaluated its diagnostic value in presenilin 1 (PSEN1) E280A mutation carriers versus non‐carriers and compared it to p‐tau217 and neurofilament light chain (NfL).
METHODS
We analyzed plasma p‐tau231 in 722 carriers and 640 non‐carriers (ages 18–75). Longitudinal data from 164 carriers and 132 non‐carriers were available, with 137 carriers and 109 non‐carriers having p‐tau231, p‐tau217, and NfL levels. Analyses used linear mixed effects models and restricted cubic splines.
RESULTS
E280A carriers had higher p‐tau231 levels than non‐carriers (9.0 ± 7.4 vs. 5.2 ± 3.4 pg/mL, P < 0.001). Baseline p‐tau231 levels correlated with age, distinguishing carriers at age 23. Rates of change differed at age 19, ≈ 25 years before cognitive impairment. In a subset, p‐tau231 changes differentiated carriers by age 20, earlier than p‐tau217 and NfL.
DISCUSSION
Plasma p‐tau231 is a sensitive biomarker for early AD detection and progression monitoring.
Highlights
Plasma phosphorylated tau (p‐tau)231 levels are associated with age in presenilin 1 carriers and non‐carriers.
Baseline p‐tau231 levels diverged between carriers and non‐carriers at age 23.
Plasma p‐tau231 changes distinguished carriers by age 19, at very early stages.
P‐tau231 longitudinal changes differentiate carriers earlier than p‐tau217 or neurofilament light chain. |
|---|---|
| AbstractList | INTRODUCTION: Plasma phosphorylated tau (p-tau)-231 is a promising biomarker for Alzheimer's disease (AD), particularly in preclinical stages. We evaluated its diagnostic value in presenilin 1 (PSEN1) E280A mutation carriers versus non-carriers and compared it to p-tau217 and neurofilament light chain (NfL). METHODS: We analyzed plasma p-tau231 in 722 carriers and 640 non-carriers (ages 18–75). Longitudinal data from 164 carriers and 132 non-carriers were available, with 137 carriers and 109 non-carriers having p-tau231, p-tau217, and NfL levels. Analyses used linear mixed effects models and restricted cubic splines. RESULTS: E280A carriers had higher p-tau231 levels than non-carriers (9.0±7.4vs. 5.2±3.4 pg/mL, P<0.001). Baseline p-tau231 levels correlated with age, distinguishing carriers at age 23. Rates of change differed at age 19, ≈ 25 years before cognitive impairment. In a subset, p-tau231 changes differentiated carriers by age 20, earlier than p-tau217 and NfL. DISCUSSION: Plasma p-tau231 is a sensitive biomarker for early AD detection and progression monitoring. Highlights: Plasma phosphorylated tau (p-tau)231 levels are associated with age in presenilin 1 carriers and non-carriers. Baseline p-tau231 levels diverged between carriers and non-carriers at age 23. Plasma p-tau231 changes distinguished carriers by age 19, at very early stages. P-tau231 longitudinal changes differentiate carriers earlier than p-tau217 or neurofilament light chain. Plasma phosphorylated tau (p-tau)-231 is a promising biomarker for Alzheimer's disease (AD), particularly in preclinical stages. We evaluated its diagnostic value in presenilin 1 (PSEN1) E280A mutation carriers versus non-carriers and compared it to p-tau217 and neurofilament light chain (NfL).INTRODUCTIONPlasma phosphorylated tau (p-tau)-231 is a promising biomarker for Alzheimer's disease (AD), particularly in preclinical stages. We evaluated its diagnostic value in presenilin 1 (PSEN1) E280A mutation carriers versus non-carriers and compared it to p-tau217 and neurofilament light chain (NfL).We analyzed plasma p-tau231 in 722 carriers and 640 non-carriers (ages 18-75). Longitudinal data from 164 carriers and 132 non-carriers were available, with 137 carriers and 109 non-carriers having p-tau231, p-tau217, and NfL levels. Analyses used linear mixed effects models and restricted cubic splines.METHODSWe analyzed plasma p-tau231 in 722 carriers and 640 non-carriers (ages 18-75). Longitudinal data from 164 carriers and 132 non-carriers were available, with 137 carriers and 109 non-carriers having p-tau231, p-tau217, and NfL levels. Analyses used linear mixed effects models and restricted cubic splines.E280A carriers had higher p-tau231 levels than non-carriers (9.0 ± 7.4 vs. 5.2 ± 3.4 pg/mL, P < 0.001). Baseline p-tau231 levels correlated with age, distinguishing carriers at age 23. Rates of change differed at age 19, ≈ 25 years before cognitive impairment. In a subset, p-tau231 changes differentiated carriers by age 20, earlier than p-tau217 and NfL.RESULTSE280A carriers had higher p-tau231 levels than non-carriers (9.0 ± 7.4 vs. 5.2 ± 3.4 pg/mL, P < 0.001). Baseline p-tau231 levels correlated with age, distinguishing carriers at age 23. Rates of change differed at age 19, ≈ 25 years before cognitive impairment. In a subset, p-tau231 changes differentiated carriers by age 20, earlier than p-tau217 and NfL.Plasma p-tau231 is a sensitive biomarker for early AD detection and progression monitoring.DISCUSSIONPlasma p-tau231 is a sensitive biomarker for early AD detection and progression monitoring.Plasma phosphorylated tau (p-tau)231 levels are associated with age in presenilin 1 carriers and non-carriers. Baseline p-tau231 levels diverged between carriers and non-carriers at age 23. Plasma p-tau231 changes distinguished carriers by age 19, at very early stages. P-tau231 longitudinal changes differentiate carriers earlier than p-tau217 or neurofilament light chain.HIGHLIGHTSPlasma phosphorylated tau (p-tau)231 levels are associated with age in presenilin 1 carriers and non-carriers. Baseline p-tau231 levels diverged between carriers and non-carriers at age 23. Plasma p-tau231 changes distinguished carriers by age 19, at very early stages. P-tau231 longitudinal changes differentiate carriers earlier than p-tau217 or neurofilament light chain. Plasma phosphorylated tau (p-tau)-231 is a promising biomarker for Alzheimer's disease (AD), particularly in preclinical stages. We evaluated its diagnostic value in presenilin 1 (PSEN1) E280A mutation carriers versus non-carriers and compared it to p-tau217 and neurofilament light chain (NfL). We analyzed plasma p-tau231 in 722 carriers and 640 non-carriers (ages 18-75). Longitudinal data from 164 carriers and 132 non-carriers were available, with 137 carriers and 109 non-carriers having p-tau231, p-tau217, and NfL levels. Analyses used linear mixed effects models and restricted cubic splines. E280A carriers had higher p-tau231 levels than non-carriers (9.0 ± 7.4 vs. 5.2 ± 3.4 pg/mL, P < 0.001). Baseline p-tau231 levels correlated with age, distinguishing carriers at age 23. Rates of change differed at age 19, ≈ 25 years before cognitive impairment. In a subset, p-tau231 changes differentiated carriers by age 20, earlier than p-tau217 and NfL. Plasma p-tau231 is a sensitive biomarker for early AD detection and progression monitoring. Plasma phosphorylated tau (p-tau)231 levels are associated with age in presenilin 1 carriers and non-carriers. Baseline p-tau231 levels diverged between carriers and non-carriers at age 23. Plasma p-tau231 changes distinguished carriers by age 19, at very early stages. P-tau231 longitudinal changes differentiate carriers earlier than p-tau217 or neurofilament light chain. INTRODUCTION Plasma phosphorylated tau (p‐tau)‐231 is a promising biomarker for Alzheimer's disease (AD), particularly in preclinical stages. We evaluated its diagnostic value in presenilin 1 (PSEN1) E280A mutation carriers versus non‐carriers and compared it to p‐tau217 and neurofilament light chain (NfL). METHODS We analyzed plasma p‐tau231 in 722 carriers and 640 non‐carriers (ages 18–75). Longitudinal data from 164 carriers and 132 non‐carriers were available, with 137 carriers and 109 non‐carriers having p‐tau231, p‐tau217, and NfL levels. Analyses used linear mixed effects models and restricted cubic splines. RESULTS E280A carriers had higher p‐tau231 levels than non‐carriers (9.0 ± 7.4 vs. 5.2 ± 3.4 pg/mL, P < 0.001). Baseline p‐tau231 levels correlated with age, distinguishing carriers at age 23. Rates of change differed at age 19, ≈ 25 years before cognitive impairment. In a subset, p‐tau231 changes differentiated carriers by age 20, earlier than p‐tau217 and NfL. DISCUSSION Plasma p‐tau231 is a sensitive biomarker for early AD detection and progression monitoring. Highlights Plasma phosphorylated tau (p‐tau)231 levels are associated with age in presenilin 1 carriers and non‐carriers. Baseline p‐tau231 levels diverged between carriers and non‐carriers at age 23. Plasma p‐tau231 changes distinguished carriers by age 19, at very early stages. P‐tau231 longitudinal changes differentiate carriers earlier than p‐tau217 or neurofilament light chain. |
| Author | Su, Yi Garcia‐Ospina, Gloria Gómez‐Ramirez, Johana Ghisays, Valentina Acosta‐Baena, Natalia Chen, Yinghua Reiman, Eric M. Villegas‐Lanau, Andres Tirado, Victoria Vila‐Castelar, Clara Tariot, Pierre N. Munoz, Claudia Pruzin, Jeremy J. Rios‐Romenets, Silvia Martínez, Jairo E. Baena, Ana Zetterberg, Henrik Giraldo‐Chica, Margarita Aguillon, David Malotaux, Vincent Guzman‐Martínez, Claudia Giudicessi, Averi Quiroz, Yakeel T. Blennow, Kaj Öhrfelt, Annika Ashton, Nicholas J. |
| AuthorAffiliation | 11 Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay Hong Kong China 2 Department of Psychiatry and Neurochemistry Inst. of Neuroscience and Physiology University of Gothenburg Mölndal Sweden 6 Department of Psychological and Brain Sciences Boston University Boston Massachusetts USA 14 Translational Genomics Research Institute Phoenix Arizona USA 1 Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA 3 Banner Alzheimer's Institute Phoenix Arizona USA 8 Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Sweden 5 Grupo de Neurociencias de Antioquia Facultad de Medicina Universidad de Antioquia Medellín Colombia 4 Banner Sun Health Research Institute Sun City Arizona USA 13 Arizona State University Phoenix Arizona USA 9 Department of Neurodegenerative Disease UCL Institute of Neurology, Queen Square London UK 10 UK Dementia Research Institute at UCL London UK 7 College of Medicine University of Arizona Phoenix Arizona USA 12 Wisconsin Al |
| AuthorAffiliation_xml | – name: 8 Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Sweden – name: 13 Arizona State University Phoenix Arizona USA – name: 2 Department of Psychiatry and Neurochemistry Inst. of Neuroscience and Physiology University of Gothenburg Mölndal Sweden – name: 7 College of Medicine University of Arizona Phoenix Arizona USA – name: 5 Grupo de Neurociencias de Antioquia Facultad de Medicina Universidad de Antioquia Medellín Colombia – name: 14 Translational Genomics Research Institute Phoenix Arizona USA – name: 9 Department of Neurodegenerative Disease UCL Institute of Neurology, Queen Square London UK – name: 1 Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA – name: 12 Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health University of Wisconsin–Madison Madison Wisconsin USA – name: 6 Department of Psychological and Brain Sciences Boston University Boston Massachusetts USA – name: 10 UK Dementia Research Institute at UCL London UK – name: 4 Banner Sun Health Research Institute Sun City Arizona USA – name: 3 Banner Alzheimer's Institute Phoenix Arizona USA – name: 11 Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay Hong Kong China |
| Author_xml | – sequence: 1 givenname: Vincent orcidid: 0000-0003-0737-9220 surname: Malotaux fullname: Malotaux, Vincent organization: Harvard Medical School – sequence: 2 givenname: Nicholas J. surname: Ashton fullname: Ashton, Nicholas J. organization: Banner Sun Health Research Institute – sequence: 3 givenname: Annika surname: Öhrfelt fullname: Öhrfelt, Annika organization: University of Gothenburg – sequence: 4 givenname: Yinghua surname: Chen fullname: Chen, Yinghua organization: Banner Alzheimer's Institute – sequence: 5 givenname: Yi surname: Su fullname: Su, Yi organization: Banner Alzheimer's Institute – sequence: 6 givenname: Gloria surname: Garcia‐Ospina fullname: Garcia‐Ospina, Gloria organization: Universidad de Antioquia – sequence: 7 givenname: Claudia surname: Guzman‐Martínez fullname: Guzman‐Martínez, Claudia organization: Universidad de Antioquia – sequence: 8 givenname: Andres surname: Villegas‐Lanau fullname: Villegas‐Lanau, Andres organization: Universidad de Antioquia – sequence: 9 givenname: Johana surname: Gómez‐Ramirez fullname: Gómez‐Ramirez, Johana organization: Universidad de Antioquia – sequence: 10 givenname: Margarita surname: Giraldo‐Chica fullname: Giraldo‐Chica, Margarita organization: Universidad de Antioquia – sequence: 11 givenname: David surname: Aguillon fullname: Aguillon, David organization: Universidad de Antioquia – sequence: 12 givenname: Victoria surname: Tirado fullname: Tirado, Victoria organization: Universidad de Antioquia – sequence: 13 givenname: Ana surname: Baena fullname: Baena, Ana organization: Universidad de Antioquia – sequence: 14 givenname: Claudia surname: Munoz fullname: Munoz, Claudia organization: Universidad de Antioquia – sequence: 15 givenname: Natalia surname: Acosta‐Baena fullname: Acosta‐Baena, Natalia organization: Universidad de Antioquia – sequence: 16 givenname: Jeremy J. surname: Pruzin fullname: Pruzin, Jeremy J. organization: Banner Alzheimer's Institute – sequence: 17 givenname: Valentina surname: Ghisays fullname: Ghisays, Valentina organization: Banner Alzheimer's Institute – sequence: 18 givenname: Silvia surname: Rios‐Romenets fullname: Rios‐Romenets, Silvia organization: Universidad de Antioquia – sequence: 19 givenname: Clara surname: Vila‐Castelar fullname: Vila‐Castelar, Clara organization: Harvard Medical School – sequence: 20 givenname: Jairo E. surname: Martínez fullname: Martínez, Jairo E. organization: Boston University – sequence: 21 givenname: Averi surname: Giudicessi fullname: Giudicessi, Averi organization: Boston University – sequence: 22 givenname: Pierre N. surname: Tariot fullname: Tariot, Pierre N. organization: University of Arizona – sequence: 23 givenname: Henrik surname: Zetterberg fullname: Zetterberg, Henrik organization: University of Wisconsin–Madison – sequence: 24 givenname: Kaj surname: Blennow fullname: Blennow, Kaj organization: Sahlgrenska University Hospital – sequence: 25 givenname: Eric M. surname: Reiman fullname: Reiman, Eric M. organization: Translational Genomics Research Institute – sequence: 26 givenname: Yakeel T. surname: Quiroz fullname: Quiroz, Yakeel T. email: yquiroz@mgh.harvard.edu organization: Boston University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40588692$$D View this record in MEDLINE/PubMed https://gup.ub.gu.se/publication/352128$$DView record from Swedish Publication Index |
| BookMark | eNp1ks1u1DAUhS1URH9gwQsg74BFWtuJE4dNFVUtII0EC9iwsZz4Zsbg2MFOqKYrXqASz8iT4GnKiC5Y2ff4u-fK9jlGB847QOg5JaeUEHam7M1pRQpGH6EjyjnLOKvqg_2-JIfoOMavhBREUP4EHRaEC1HW7AjdfrQqDgqPv3_-mtTMcoqNw9MG8BgggjM2lRRfMkEarObJRz8oi7UfjFNuwo292YAZILyMWJsIKgL-ZpwOoN_gBnfBx5isI3ST8S51Kqex9W5tplmbndD5jQ8TjqnePkWPe2UjPLtfT9Dnq8tPF--y1Ye37y-aVdYVtKSZLuq860XORSdqIlpRtj2hWgMnbSEUy5PSVVzrtqCsKjVnrIc8XViVJaOFyE9QtvjGaxjnVo7BDCpspVdGrudRJmk9ywgy54yyHX--8AkeQHfgpqDsg7aHJ85s5Nr_kJQxIqq6TA6v7h2C_z5DnORgYgfWKgd-jjJnjIuqYjVN6It_h-2n_P20BLxegLvXDdDvEUrkLhAyBULeBSKxZwt7bSxs_w_KZvVl6fgDZ6O6ZA |
| Cites_doi | 10.1001/jamaneurol.2020.4201 10.1038/s41591-021-01382-x 10.1007/s00401-021-02275-6 10.1016/j.jalz.2011.03.008 10.1002/ana.26308 10.1016/S1474-4422(20)30137-X 10.1038/s41591-022-02074-w 10.1001/jamaneurol.2015.4851 10.1038/s43587-023-00405-1 10.1093/brain/awac333 10.1016/S1474-4422(20)30071-5 10.1038/s43587-023-00403-3 10.1001/jama.2020.12134 10.1001/jamaneurol.2014.3314 10.1016/S1474-4422(12)70228-4 10.1186/s13024-023-00605-8 10.1001/jamaneurol.2017.4907 10.1016/0022-3956(75)90026-6 10.1038/s41467-023-40775-z 10.1111/ejn.16085 10.1111/j.1532-5415.1983.tb06290.x 10.1002/(SICI)1098-1004(1997)10:3<186::AID-HUMU2>3.0.CO;2-H 10.1038/s41591-018-0304-3 10.15252/emmm.201911170 10.1016/S1474-4422(10)70323-9 |
| ContentType | Journal Article |
| Copyright | 2025 The Author(s). published by Wiley Periodicals LLC on behalf of Alzheimer's Association. 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. |
| Copyright_xml | – notice: 2025 The Author(s). published by Wiley Periodicals LLC on behalf of Alzheimer's Association. – notice: 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTPV AOWAS F1U |
| DOI | 10.1002/alz.70421 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Göteborgs universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | MALOTAUX et al |
| EISSN | 1552-5279 |
| EndPage | n/a |
| ExternalDocumentID | oai_gup_ub_gu_se_352128 PMC12208796 40588692 10_1002_alz_70421 ALZ70421 |
| Genre | researchArticle Journal Article |
| GrantInformation_xml | – fundername: National Institute on Aging – fundername: National Institute of Neurological Disorders and Stroke – fundername: Alzheimer's Prevention Initiative (API) Autosomal Dominant AD Trial – fundername: NIH/NIA – fundername: NIA NIH HHS – fundername: NINDS NIH HHS – fundername: ; |
| GroupedDBID | --- --K --M .~1 0R~ 1B1 1OC 1~. 1~5 24P 33P 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 8FI 8FJ 8P~ AAEDT AAIKJ AAKOC AALRI AAMMB AANLZ AAOAW AAXLA AAXUO AAYCA AAYWO ABBQC ABCQJ ABCUV ABIVO ABJNI ABMAC ABMZM ABUWG ABWVN ACCMX ACCZN ACGFS ACGOF ACPOU ACRPL ACVFH ACXQS ADBBV ADBTR ADCNI ADEZE ADHUB ADKYN ADMUD ADNMO ADPDF ADVLN ADZMN AEFGJ AEIGN AEKER AENEX AEUPX AEUYR AEVXI AFKRA AFPUW AFTJW AFWVQ AGHFR AGHNM AGUBO AGWIK AGXDD AGYEJ AIDQK AIDYY AIGII AITUG AIURR AJRQY AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS ALUQN AMRAJ AMYDB ANZVX AZQEC BENPR BFHJK BLXMC C45 CCPQU DCZOG EBS EJD EMOBN EO8 EO9 EP2 EP3 F5P FDB FEDTE FIRID FNPLU FYUFA G-Q GBLVA HMCUK HVGLF HX~ HZ~ IHE J1W K9- LATKE LEEKS M0R M41 MO0 MOBAO N9A NAPCQ O-L O9- OAUVE OVD OVEED OZT P-8 P-9 P2P PC. PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PSYQQ Q38 QTD RIG ROL RPM RPZ SDF SDG SEL SES SSZ SUPJJ TEORI UKHRP ~G- AAYXX CITATION EFLBG PUEGO ~HD CGR CUY CVF ECM EIF NPM 7X8 5PM ADTPV AOWAS F1U |
| ID | FETCH-LOGICAL-c4161-d493cf8358c8908b86bf01dde50b48a23b86c75ddb41276d522fe3869a6621483 |
| IEDL.DBID | 24P |
| ISSN | 1552-5260 1552-5279 |
| IngestDate | Tue Sep 09 23:12:42 EDT 2025 Thu Aug 21 18:33:20 EDT 2025 Fri Sep 05 15:46:13 EDT 2025 Mon Jul 21 06:01:56 EDT 2025 Thu Sep 25 00:51:17 EDT 2025 Fri Aug 01 09:20:32 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Alzheimer's disease, autosomal dominant Alzheimer's disease biomarkers, plasma, presenilin 1, phosphorylated tau231 |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4161-d493cf8358c8908b86bf01dde50b48a23b86c75ddb41276d522fe3869a6621483 |
| Notes | Kaj Blennow, Eric M. Reiman, and Yakeel T. Quiroz are co‐senior authors. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-0737-9220 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Falz.70421 |
| PMID | 40588692 |
| PQID | 3225877291 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | swepub_primary_oai_gup_ub_gu_se_352128 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12208796 proquest_miscellaneous_3225877291 pubmed_primary_40588692 crossref_primary_10_1002_alz_70421 wiley_primary_10_1002_alz_70421_ALZ70421 |
| PublicationCentury | 2000 |
| PublicationDate | July 2025 |
| PublicationDateYYYYMMDD | 2025-07-01 |
| PublicationDate_xml | – month: 07 year: 2025 text: July 2025 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Alzheimer's & dementia |
| PublicationTitleAlternate | Alzheimers Dement |
| PublicationYear | 2025 |
| Publisher | John Wiley and Sons Inc |
| Publisher_xml | – name: John Wiley and Sons Inc |
| References | 2021; 27 2023; 58 2023; 14 2023; 18 2019; 11 2015; 72 2023; 146 2022; 91 1983; 31 2020; 324 1975; 12 2011; 10 2016; 73 2021; 141 2023; 3 2012; 11 2022; 28 2011; 7 2020; 19 2021; 78 2018; 4 1997; 10 2019; 25 1988; 24 2007; 45 2018; 75 e_1_2_8_28_1 e_1_2_8_29_1 Rios‐Romenets S (e_1_2_8_16_1) 2018; 4 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 Aguirre‐Acevedo DC (e_1_2_8_19_1) 2007; 45 e_1_2_8_17_1 Reisberg B (e_1_2_8_18_1) 1988; 24 e_1_2_8_13_1 e_1_2_8_14_1 Mila‐Aloma M (e_1_2_8_11_1) 2022; 28 Tariot PN (e_1_2_8_15_1) 2018; 4 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_12_1 e_1_2_8_30_1 |
| References_xml | – volume: 141 start-page: 709 year: 2021 end-page: 724 article-title: Plasma p‐tau231: a new biomarker for incipient Alzheimer's disease pathology publication-title: Acta Neuropathol – volume: 28 start-page: 2555 year: 2022 end-page: 2562 article-title: Differential roles of Abeta42/40, p‐tau231 and p‐tau217 for Alzheimer's trial selection and disease monitoring publication-title: Nat Med – volume: 324 start-page: 772 year: 2020 end-page: 781 article-title: Discriminative accuracy of plasma phospho‐tau217 for Alzheimer disease vs other neurodegenerative disorders publication-title: JAMA – volume: 10 start-page: 213 year: 2011 end-page: 220 article-title: Pre‐dementia clinical stages in presenilin 1 E280A familial early‐onset Alzheimer's disease: a retrospective cohort study publication-title: Lancet Neurol – volume: 11 year: 2019 article-title: Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease publication-title: EMBO Mol Med – volume: 19 start-page: 513 year: 2020 end-page: 521 article-title: Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross‐sectional and longitudinal cohort study publication-title: Lancet Neurol – volume: 19 start-page: 422 year: 2020 end-page: 433 article-title: Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts publication-title: Lancet Neurol – volume: 91 start-page: 548 year: 2022 end-page: 560 article-title: Plasma p‐tau231, p‐tau181, PET biomarkers, and cognitive change in older adults publication-title: Ann Neurol – volume: 3 start-page: 506 year: 2023 end-page: 519 article-title: Blood biomarkers for Alzheimer's disease in clinical practice and trials publication-title: Nat Aging – volume: 24 start-page: 653 year: 1988 end-page: 659 article-title: Functional assessment staging (FAST) publication-title: Psychopharmacol Bull – volume: 18 start-page: 18 year: 2023 article-title: Plasma phospho‐tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications publication-title: Mol Neurodegener – volume: 58 start-page: 3132 year: 2023 end-page: 3149 article-title: The performance of plasma phosphorylated tau231 in detecting Alzheimer's disease: a systematic review with meta‐analysis publication-title: Eur J Neurosci – volume: 11 start-page: 1048 year: 2012 end-page: 1056 article-title: Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case‐control study publication-title: Lancet Neurol – volume: 31 start-page: 59 year: 1983 end-page: 60 article-title: Opportunities for and obstacles to treatments for dementias publication-title: J Am Geriatr Soc – volume: 78 start-page: 149 year: 2021 end-page: 156 article-title: Associations of plasma phospho‐Tau217 levels with Tau positron emission tomography in early Alzheimer disease publication-title: JAMA Neurol – volume: 146 start-page: 1592 year: 2023 end-page: 1601 article-title: Head‐to‐head comparison of 10 plasma phospho‐tau assays in prodromal Alzheimer's disease publication-title: Brain – volume: 14 start-page: 5120 year: 2023 article-title: Effect of apolipoprotein genotype and educational attainment on cognitive function in autosomal dominant Alzheimer's disease publication-title: Nat Commun – volume: 73 start-page: 431 year: 2016 end-page: 438 article-title: Cognitive decline in a colombian kindred with autosomal dominant Alzheimer disease: a retrospective cohort study publication-title: JAMA Neurol – volume: 12 start-page: 189 year: 1975 end-page: 198 article-title: “Mini‐mental state”. A practical method for grading the cognitive state of patients for the clinician publication-title: J Psychiatr Res – volume: 27 start-page: 954 year: 2021 end-page: 963 article-title: Biomarkers for neurodegenerative diseases publication-title: Nat Med – volume: 4 start-page: 283 year: 2018 end-page: 287 article-title: Adherence/Retention Alzheimer's prevention initiative Colombia plan publication-title: Alzheimers Dement – volume: 25 start-page: 277 year: 2019 end-page: 283 article-title: Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease publication-title: Nat Med – volume: 10 start-page: 186 year: 1997 end-page: 195 article-title: E280A PS‐1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles publication-title: Hum Mutat – volume: 4 start-page: 150 year: 2018 end-page: 160 article-title: The Alzheimer's prevention initiative autosomal‐dominant Alzheimer's disease trial: a study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort publication-title: Alzheimers Dement – volume: 45 start-page: 655 year: 2007 end-page: 660 article-title: [Validity and reliability of the CERAD‐Col neuropsychological battery] publication-title: Rev Neurol – volume: 72 start-page: 316 year: 2015 end-page: 324 article-title: Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross‐sectional study publication-title: JAMA Neurol – volume: 7 start-page: 270 year: 2011 end-page: 279 article-title: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the national institute on aging‐Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease publication-title: Alzheimers Dement – volume: 28 start-page: 1797 year: 2022 end-page: 1801 article-title: Plasma p‐tau231 and p‐tau217 as state markers of amyloid‐beta pathology in preclinical Alzheimer's disease publication-title: Nat Med – volume: 3 start-page: 661 year: 2023 end-page: 669 article-title: Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies publication-title: Nat Aging – volume: 75 start-page: 548 year: 2018 end-page: 556 article-title: Association between amyloid and Tau accumulation in young adults with autosomal dominant Alzheimer disease publication-title: JAMA Neurol – volume: 28 start-page: 1797 year: 2022 ident: e_1_2_8_11_1 article-title: Plasma p‐tau231 and p‐tau217 as state markers of amyloid‐beta pathology in preclinical Alzheimer's disease publication-title: Nat Med – ident: e_1_2_8_9_1 doi: 10.1001/jamaneurol.2020.4201 – ident: e_1_2_8_2_1 doi: 10.1038/s41591-021-01382-x – ident: e_1_2_8_10_1 doi: 10.1007/s00401-021-02275-6 – ident: e_1_2_8_20_1 doi: 10.1016/j.jalz.2011.03.008 – volume: 4 start-page: 283 year: 2018 ident: e_1_2_8_16_1 article-title: Adherence/Retention Alzheimer's prevention initiative Colombia plan publication-title: Alzheimers Dement – ident: e_1_2_8_12_1 doi: 10.1002/ana.26308 – ident: e_1_2_8_23_1 doi: 10.1016/S1474-4422(20)30137-X – volume: 45 start-page: 655 year: 2007 ident: e_1_2_8_19_1 article-title: [Validity and reliability of the CERAD‐Col neuropsychological battery] publication-title: Rev Neurol – volume: 24 start-page: 653 year: 1988 ident: e_1_2_8_18_1 article-title: Functional assessment staging (FAST) publication-title: Psychopharmacol Bull – ident: e_1_2_8_13_1 doi: 10.1038/s41591-022-02074-w – ident: e_1_2_8_25_1 doi: 10.1001/jamaneurol.2015.4851 – ident: e_1_2_8_30_1 doi: 10.1038/s43587-023-00405-1 – ident: e_1_2_8_31_1 doi: 10.1093/brain/awac333 – ident: e_1_2_8_8_1 doi: 10.1016/S1474-4422(20)30071-5 – ident: e_1_2_8_3_1 doi: 10.1038/s43587-023-00403-3 – ident: e_1_2_8_5_1 doi: 10.1001/jama.2020.12134 – ident: e_1_2_8_27_1 doi: 10.1001/jamaneurol.2014.3314 – ident: e_1_2_8_28_1 doi: 10.1016/S1474-4422(12)70228-4 – ident: e_1_2_8_4_1 doi: 10.1186/s13024-023-00605-8 – ident: e_1_2_8_29_1 doi: 10.1001/jamaneurol.2017.4907 – ident: e_1_2_8_17_1 doi: 10.1016/0022-3956(75)90026-6 – ident: e_1_2_8_26_1 doi: 10.1038/s41467-023-40775-z – ident: e_1_2_8_7_1 doi: 10.1111/ejn.16085 – ident: e_1_2_8_21_1 doi: 10.1111/j.1532-5415.1983.tb06290.x – ident: e_1_2_8_22_1 doi: 10.1002/(SICI)1098-1004(1997)10:3<186::AID-HUMU2>3.0.CO;2-H – ident: e_1_2_8_24_1 doi: 10.1038/s41591-018-0304-3 – ident: e_1_2_8_6_1 doi: 10.15252/emmm.201911170 – volume: 4 start-page: 150 year: 2018 ident: e_1_2_8_15_1 article-title: The Alzheimer's prevention initiative autosomal‐dominant Alzheimer's disease trial: a study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort publication-title: Alzheimers Dement – ident: e_1_2_8_14_1 doi: 10.1016/S1474-4422(10)70323-9 |
| SSID | ssj0040815 |
| Score | 2.4304292 |
| Snippet | INTRODUCTION
Plasma phosphorylated tau (p‐tau)‐231 is a promising biomarker for Alzheimer's disease (AD), particularly in preclinical stages. We evaluated its... Plasma phosphorylated tau (p-tau)-231 is a promising biomarker for Alzheimer's disease (AD), particularly in preclinical stages. We evaluated its diagnostic... INTRODUCTION: Plasma phosphorylated tau (p-tau)-231 is a promising biomarker for Alzheimer's disease (AD), particularly in preclinical stages. We evaluated its... |
| SourceID | swepub pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | e70421 |
| SubjectTerms | Adult Aged Alzheimer Disease - blood Alzheimer Disease - diagnosis Alzheimer Disease - genetics Alzheimer's disease Alzheimer's disease, autosomal dominant Alzheimer's disease autosomal dominant Alzheimer's disease biomarkers Biomarkers - blood biomarkers, plasma, presenilin 1, phosphorylated tau231 Cohort Studies Cross-Sectional Studies Female Humans Longitudinal Studies Male Middle Aged Mutation - genetics Neurofilament Proteins - blood Neurosciences Neurovetenskaper phosphorylated tau231 Phosphorylation plasma presenilin 1 Presenilin-1 - genetics tau Proteins - blood |
| Title | Plasma p‐tau231 in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross‐sectional and longitudinal cohort study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Falz.70421 https://www.ncbi.nlm.nih.gov/pubmed/40588692 https://www.proquest.com/docview/3225877291 https://pubmed.ncbi.nlm.nih.gov/PMC12208796 https://gup.ub.gu.se/publication/352128 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Pi9QwFA_L7sWLKP6rq0MUUS9107RNUz1VmWURXQZxYfAS0ibdLc60w7S97MkvIPgZ_SS-l05HyiJ4KaVN0qbv9eX3kpffI-RFzgQzESK3NNF-JEUKdrAUfqpLZhIk1BK43_nzuTi7iD4u4-UBeTfuhRn4IfYTbvhnOHuNP7jO25O_pKF6df0mAZUD1-cIQH2I6s2jxWiGIxjrYkeWGqO3JdhIK8T4yb7qdDC6gTBvBkru6ESnSNYNRad3yO0dhqTZIPS75MDW98jPBeDgtaab3z9-dboHQEWrmgK8oxu3w6iCHtOAzrlkGdV917TNGhoxzRALQ7PV9ZWt1nb7qqW7VRv6vcJwR_OWZtR1AJpuXegWPl7Xhq4aTHfUG0ytRTHX7rajjrD2Prk4nX_9cObvci34Bbo4vonSsCgBjslCpkzmUuQlC8D2xSyPpOYhXCmS2Jg8CngiDMC20oYgWi0EB5cqfEAO66a2jwi1ZVBoHhSlAKwVpzaV4EKC2YgsjMdGBB55Pn50tRkoNdRAnswVSEY5yXjk2SgOBQqPqxi6tk3fKrRAEn0CKPNwEM--GUCfEt6Je0ROBLcvgGTa0zt1deVItQPOmUxS4ZGXg4wndS77jYJLl71qrQpxv7P0yGunA__ug8o-fXMnj_-_6DG5xTHDsAsIfkIOu21vnwLs6fKZU284JstkRo7ez88XX2ZuduoPttgE0Q |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELaqcoALAvEXaMEgBFxCncRxHMQlQq0W2FY9tFLFxXJip43YTVab5NITL4DEM_IkzDibRVGFxC1ybCf22ONv7PE3hLzOmWCGI3JLE-1zKVLQg6XwU10ykyChlsD7zscnYnbOv1zEFzvk43gXZuCH2G644cxw-honOG5IH_xlDdWL6_cJjDmwfW5xAaYL8jrz01EPc1jsYseWGqO5JdjIK8TCg23R6Wp0A2Le9JTc8IlOoaxbi47ukbsbEEmzQer3yY6tH5CfpwCEl5qufv_41ekeEBWtagr4jq7cFaMKmkwDehhKllHdd03bLKES0wzOMDRbXF_ZamnXb1u6Obah3yv0dzQfaEZdA6Dq1vlu4ed1beiiwXhHvcHYWhSD7a476hhrH5Lzo8OzTzN_E2zBL9DG8Q1Po6IEPCYLmTKZS5GXLADlF7OcSx1GkFIksTE5D8JEGMBtpY1AtlpA33MZPSK7dVPbJ4TaMih0GBSlALAVpzaVYEOC3uAWFmQjAo-8GjtdrQZODTWwJ4cKJKOcZDzychSHghGPxxi6tk3fKlRBEo0CyPN4EM-2GoCfEv4p9IicCG6bAdm0p2_q6sqxagdhyGSSCo-8GWQ8KXPZrxQkXfaqtSrCC8_SI-_cGPh3G1Q2_-Yenv5_1hfk9uzseK7mn0--PiN3Qgw37LyD98hut-7tPmCgLn_uhvofRWcEpg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELaqVkJcEBV_KRQMQsAl1HEcxymnCLoqUKo9UKniYjmx00bsJtEmufTUF0DiGXmSjp3NoqhC4hY5thNnxuNv4vE3CL3OCCeaWeSWxMpngidgBwvuJ6ogOraEWtyed_52yo_P2Jfz6HwLfRjPwgz8EJsfbnZmOHttJ3iji4O_pKFqcfU-BpUD12eHgd5Z9aZsPpphBmtd5MhSI-ttcTLSChF6sGk6XYxuIczbgZJrOtEpknVL0ew-urfGkDgdhL6Ltkz1AP2aAw5eKtz8uf7dqR4AFS4rDPAON-6EUQkjxgE-ooKkWPVd3dZL6ETXQywMThdXl6ZcmtXbFq93bfDP0oY76kOcYjcA6Lp1oVv28arSeFHbdEe9tqm1sM21u-qwI6x9iM5mR98_HvvrXAt-bl0cX7MkzAuAYyIXCRGZ4FlBArB9EcmYUDSEkjyOtM5YQGOuAbYVJgTRKs4puFThI7Rd1ZV5grApglzRIC84YK0oMYkAFxLMBjOwHmseeOjV-NFlM1BqyIE8mUqQjHSS8dDLURwSFN7uYqjK1H0rrQUS1ieAOo8H8Wy6AfQp4J2oh8REcJsKlkx7eqcqLx2pdkApEXHCPfRmkPGkzUXfSCi66GVrZGjPOwsPvXM68O8xyPTkh7vY-_-qL9Cd-aeZPPl8-vUpukttsmEXG_wMbXer3uwDAuqy507TbwDdvQPh |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+p-tau231+in+the+presenilin+1+E280A+autosomal+dominant+Alzheimer%27s+disease+kindred%3A+A+cross-sectional+and+longitudinal+cohort+study&rft.jtitle=Alzheimer%27s+%26+dementia&rft.au=Malotaux%2C+Vincent&rft.au=Ashton%2C+Nicholas+J.&rft.au=%C3%96hrfelt%2C+Annika&rft.au=Chen%2C+Yinghua&rft.date=2025-07-01&rft.issn=1552-5279&rft.volume=21&rft.issue=7&rft_id=info:doi/10.1002%2Falz.70421&rft.externalDocID=oai_gup_ub_gu_se_352128 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1552-5260&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1552-5260&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1552-5260&client=summon |